Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations. Its product pipeline consists of COM701, a monoclonal antibody designed to block the interaction of PVRIG with its cognate ligand, PVRL2; CGEN-15001T, an immuno-oncology therapeutic program for ILDR2; and COM902, a therapeutic antibody candidate for its TIGIT program. The company's pipeline also comprises therapeutic proteins include CGEN-15001, a fusion protein drug candidate for autoimmune diseases, including extracellular domain of ILDR2 and an IgG Fc domain. Compugen Ltd. has a clinical trial collaboration with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb's programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors. The company was incorporated in 1993 and is headquartered in Holon, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CGEN
Previous Symbol
CUSIPN/A
Phone972-3765-8585
Debt
Debt-to-Equity RatioN/A
Current Ratio4.61
Quick Ratio4.61
Price-To-Earnings
Trailing P/E Ratio-4.51
Forward P/E Ratio-7.39
P/E GrowthN/A
Sales & Book Value
Annual Sales$710,000.00
Price / Sales234.78
Cash FlowN/A
Price / CashN/A
Book Value$0.74 per share
Price / Book4.39
Profitability
EPS (Most Recent Fiscal Year)($0.72)
Net Income$-37,060,000.00
Net MarginsN/A
Return on Equity-65.06%
Return on Assets-50.06%
Miscellaneous
Employees101
Outstanding Shares51,290,000
Market Cap$161.06 million
OptionableOptionable
Compugen (NASDAQ:CGEN) Frequently Asked Questions
What is Compugen's stock symbol?
Compugen trades on the NASDAQ under the ticker symbol "CGEN."
How were Compugen's earnings last quarter?
Compugen Ltd. (NASDAQ:CGEN) issued its earnings results on Wednesday, November, 7th. The biotechnology company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.07. The biotechnology company earned $7.80 million during the quarter, compared to analyst estimates of $7.80 million. View Compugen's Earnings History.
When is Compugen's next earnings date?
What price target have analysts set for CGEN?
2 brokers have issued 12 month price objectives for Compugen's shares. Their predictions range from $9.00 to $9.00. On average, they anticipate Compugen's stock price to reach $9.00 in the next year. This suggests a possible upside of 176.9% from the stock's current price. View Analyst Price Targets for Compugen.
What is the consensus analysts' recommendation for Compugen?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Compugen.
Has Compugen been receiving favorable news coverage?
Press coverage about CGEN stock has been trending somewhat negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Compugen earned a news impact score of -2.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.
Who are some of Compugen's key competitors?
Some companies that are related to Compugen include Gritstone Oncology (GRTS), Adaptimmune Therapeutics (ADAP), Scholar Rock (SRRK), Mesoblast (MESO), NanoString Technologies (NSTG), Replimune Group (REPL), PDL BioPharma (PDLI), La Jolla Pharmaceutical (LJPC), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Nightstar Therapeutics (NITE), Krystal Biotech (KRYS), Sutro Biopharma (STRO), Cellular Biomedicine Group (CBMG) and LogicBio Therapeutics (LOGC).
Who are Compugen's key executives?
Compugen's management team includes the folowing people:
- Dr. Anat Cohen-Dayag, Chief Exec. Officer, Pres and Director (Age 51)
- Mr. Ari Krashin, Chief Financial and Operating Officer (Age 45)
- Mr. Kirk A. Christoffersen MBA, Sr. VP of Corp. and Bus. Devel. (Age 49)
- Dr. Zurit Levine Ph.D., VP of Research & Discovery (Age 50)
- Dr. John J. Hunter, VP of Antibody R&D (Age 55)
Who are Compugen's major shareholders?
Compugen's stock is owned by a variety of of institutional and retail investors. Top institutional investors include ARK Investment Management LLC (13.46%), Taylor Frigon Capital Management LLC (1.15%), Renaissance Technologies LLC (0.52%) and Aviance Capital Management LLC (0.08%).
Which major investors are selling Compugen stock?
CGEN stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC.
Which major investors are buying Compugen stock?
CGEN stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Aviance Capital Management LLC and Renaissance Technologies LLC.
How do I buy shares of Compugen?
Shares of CGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Compugen's stock price today?
One share of CGEN stock can currently be purchased for approximately $3.25.
How big of a company is Compugen?
Compugen has a market capitalization of $161.06 million and generates $710,000.00 in revenue each year. The biotechnology company earns $-37,060,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis. Compugen employs 101 workers across the globe.
What is Compugen's official website?
How can I contact Compugen?
Compugen's mailing address is AZRIELI CENTER 26 HAROKMIM STREET BUILDING D, HOLON L3, 5885849. The biotechnology company can be reached via phone at 972-3765-8585 or via email at [email protected]
MarketBeat Community Rating for Compugen (NASDAQ CGEN)
MarketBeat's community ratings are surveys of what our community members think about Compugen and other stocks. Vote "Outperform" if you believe CGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
